GU Cancers Symposium 2014 - 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III ALSYMPCA study - Poster

SAN FRANCISCO, CA USA ( - Presented by S. Nilsson,1 N. Vogelzang,2 O. Sartor,3 D. Bottomley,4 R. Coleman,5 I. Skjorestad,6 M. Wahba,7 and C. Parker8 at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

Nilsson ASCOGU 2014 thumb

1Karolinska University Hospital, Stockholm, Sweden; 2Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA; 3Tulane Cancer Center, New Orleans, LA, USA; 4St. James Hospital, Leeds, UK; 5Weston Park Hospital, Sheffield, UK; 6Algeta ASA, Oslo, Norway; 7Bayer HealthCare, Whippany, NJ, USA; 8The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK 

Click HERE to read an exclusive report by a UroToday medical writer

Click HERE to listen to an exclusive interview with one of the authors of this study

View Full 2014 GU Cancers Symposium Coverage